Indegene Ltd. experienced a notable surge in its stock price, rising almost 5% in Friday's trading session. The upward movement followed an upgrade from Motilal Oswal Financial Services (MOFSL), which changed its rating on the stock from 'Neutral' to 'Buy'.
Why the Upgrade?
MOFSL's decision to upgrade Indegene's rating stems from several key factors, including strong growth prospects within the life sciences and pharmaceutical outsourcing sector. The brokerage also highlighted Indegene's consulting-led business model and the increasing integration and adoption of artificial intelligence (AI) in its operations as significant positives. Furthermore, MOFSL anticipates that operating leverage will contribute to a recovery in Indegene's profit margins.
Global life sciences and pharma companies are increasingly turning to outsourcing to streamline costs, accelerate product launches, access specialized talent, and manage fluctuating content demands related to new drug introductions. External partners like Indegene are well-positioned to scale teams as needed and optimize medical, legal, and regulatory review processes.
Target Price and Financial Projections
Motilal Oswal has set a target price of Rs 708 for Indegene, valuing the stock at 25 times its estimated FY28 earnings per share. This target represents an upside of approximately 19% from the brokerage's reference price of Rs 595.
For the first quarter of FY27, Indegene reported a robust revenue increase of 39.7% year-on-year, reaching Rs 1,063.1 crore. Enterprise commercial solutions accounted for the largest share of this revenue, growing 75.5% year-on-year to Rs 750.5 crore. Enterprise medical solutions revenue also saw a healthy increase of 24.7%, totaling Rs 273.2 crore.
MOFSL projects Indegene's revenue, EBIT (Earnings Before Interest and Taxes), and PAT (Profit After Tax) to grow at Compound Annual Growth Rates (CAGRs) of around 19%, 29%, and 27% respectively, in INR terms over FY26-28. The brokerage also expects EBITDA margins to recover to 19-20% by Q4 FY27, driven by operating leverage.
Client Diversification
The brokerage also noted improving client diversification, a positive indicator for future stability. The contribution from Indegene's top client decreased to 9% in Q1 FY27 from 14.3% in Q1 FY25. Similarly, the share of the top five clients collectively fell to 30.4% from 40.7% over the same period. Indegene now serves 54 clients generating over $1 million in annual revenue, with three clients contributing more than $25 million each.